stockrow
Friday 6 November 2026
Export ICLR’s income statement to Excel — free account
ICON PLC
ICLR Healthcare Diagnostics & Research
ICON PLC’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.76% from fiscal 2024.
- Revenue
- −2.86%
- EPS
- +143.2%
- Free cash flow
- −8.01%
- Total debt
- −0.86%
Quarter to September 2026, against a year earlier
203.06
1.41
+0.70%
Follow ICLR
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
29.07 | 295.83 | 49.91 | 66.09 |
+8 more quarters Free account |
P/S ratio |
1.59 | 1.61 | 1.02 | 1.73 | |
P/FCF ratio |
15.26 | 15.10 | 11.17 | 16.58 | |
P/Operating CF |
37.89 | 47.46 | 50.74 | 61.03 | |
P/B ratio |
1.43 | 1.42 | 0.91 | 1.55 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.06 | 1.91 | 1.34 | 2.07 | |
EV/EBITDA |
15.62 | 23.71 | 14.48 | 20.64 | |
EV/Operating CF |
16.47 | 14.78 | 11.88 | 16.45 | |
EV/FCF |
19.75 | 17.89 | 14.63 | 19.77 | |
Quick Ratio |
0.90 | 0.66 | 0.75 | 0.72 | |
Current Ratio |
1.32 | 0.95 | 1.14 | 1.10 | |
Net Debt/EBITDA |
8.76 | 10.77 | 9.96 | 9.24 | |
Debt/Assets |
20.80% | 20.67% | 20.81% | 20.91% | |
Debt/Equity |
0.37 | 0.36 | 0.37 | 0.37 | |
Asset Turnover |
0.50 | 0.50 | 0.50 | 0.50 | |
Operating CF/Net income |
2.83 | 3.88 | 1.59 | 1.57 | |
Capex/Depreciation |
(0.40) | (0.47) | (0.34) | (0.66) | |
Interest Coverage |
3.00 | 2.83 | 3.62 | 4.20 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
9.72% | 9.42% | 9.86% | 8.51% | |
Intangible Assets out of Total Assets |
0.73 | 0.72 | 0.73 | 0.74 | |
Share Based Compensation of Revenue |
0.85% | 0.89% | 1.36% | 1.40% | |
Graham Net Nets |
(0.27) | (0.25) | (0.40) | (0.25) | |
Graham Number |
124.94 | 40.15 | 77.84 | 85.28 | |
Earnings Yield |
3.44% | 0.34% | 2.00% | 1.51% | |
Free Cash Flow Yield |
6.55% | 6.62% | 8.96% | 6.03% | |
Revenue per Share |
26.32 | 26.85 | 26.56 | 26.94 | |
Operating CF per Share |
4.49 | 3.66 | 2.18 | 2.99 | |
Capex per Share |
(0.49) | (0.55) | (0.40) | (0.76) | |
Free Cash Flow per Share |
3.99 | 3.11 | 1.78 | 2.23 | |
Cash per Share |
10.52 | 12.08 | 9.99 | 8.25 | |
Shareholders Equity per Share |
118.64 | 122.04 | 121.45 | 117.23 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
118.64 | 122.04 | 121.45 | 117.23 | |
Free Cash Flow |
307.15 | 238.85 | 136.24 | 174.83 | |
Working Capital |
872.72 | (186.02) | 437.80 | 305.50 | |
Capital Expenditures |
(37.99) | (42.42) | (30.77) | (59.33) | |
Net Current Asset Value |
(3,473.63) | (3,273.51) | (3,411.39) | (3,574.72) | |
EV/EBIT |
23.57 | 53.33 | 28.50 | 38.49 | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.03 | |
Price to Operating Income |
18.21 | 45.02 | 21.75 | 32.27 | |
| Other line items | |||||
Average Receivables |
1,616.52 | 1,591.08 | 1,573.00 | 1,604.12 | |
Average Payables |
99.65 | 106.37 | 109.01 | 182.57 | |
Average Assets |
16,374.91 | 16,501.31 | 16,521.01 | 16,452.30 | |
Average Common Equity |
9,231.08 | 9,466.62 | 9,400.58 | 9,317.37 |
Columns are period end dates · fundamentals updated 2 Nov 2026